Yatharth plans Rs 3,150 crore Advent investment pending approvals

Yatharth Hospitals plans to receive Rs 3,150 crore in primary capital from Advent for a 24.9% minority stake, pending regulatory approvals, with the Tyagi family expected to retain about 42% after dilution; the proposal follows Q2 FY27 revenue of Rs 431.4 crore, up 52% year on year.

What is Advent investing in Yatharth?

Advent plans to invest Rs 3,150 crore of primary capital in Yatharth for a 24.9% strategic minority stake, subject to regulatory approvals. The presentation does not give a transaction completion date, identify the regulators involved or specify when the capital would be received.

Yatharth presents the proposed relationship as a strategic partnership that combines its healthcare platform with Advent’s acquisition and scaling capabilities. The company cites Advent’s 460 investments in 45 countries, more than 55 healthcare investments and more than 35 years of healthcare experience as the credentials relevant to the proposed next phase of growth.

How would Advent's stake change Yatharth ownership?

Advent’s planned 24.9% holding would leave the Tyagi family as Yatharth’s largest shareholder at about 42% after dilution. The company describes Advent’s position as a minority strategic stake, so the disclosed structure does not indicate a transfer of majority ownership.

Yatharth says the Tyagi family would continue to guide its long-term vision with support from the existing leadership team. Its institutional-development slide also identifies a diverse board, key managerial personnel, hospital chief executive officers, medical directors, auditors, systems and processes, alongside the proposed 24.9% Advent ownership.

The post-dilution figures establish the stated balance between promoter continuity and an institutional partner: about 42% for the Tyagi family and 24.9% for Advent. Yatharth does not disclose the ownership percentages of other shareholders, board rights, transaction valuation or the number of shares to be issued in the presentation.

What financial performance supports Yatharth's proposal?

Yatharth reported Q2 FY27 revenue of Rs 431.4 crore, earnings before interest, tax, depreciation and amortisation (EBITDA) of Rs 102 crore, and profit after tax (PAT) of Rs 48.5 crore. Revenue increased 52% from Rs 283 crore in Q2 FY26, EBITDA rose 50% from Rs 68.1 crore, and PAT increased 17% from Rs 41.3 crore.

Sequentially, Q2 FY27 revenue rose 10% from Rs 392.7 crore in Q1 FY27, while EBITDA increased 11% from Rs 91.7 crore and PAT rose 7% from Rs 45.4 crore. Reported EBITDA margin moved to 23.6% in Q2 FY27 from 23.3% in Q1 FY27, although it remained below the 24.1% reported in Q2 FY26.

For H1 FY27, Yatharth recorded revenue of Rs 824.1 crore, up 52% year on year, EBITDA of Rs 193.7 crore, up 44%, and PAT of Rs 93.9 crore, up 13%. Reported EBITDA margin was 23.5%, versus 24.7% in H1 FY26, while the company reported adjusted EBITDA margin of 28.1% after excluding ramp-up losses at Model Town and Faridabad Sector-20.

How are newer hospitals changing Yatharth's revenue mix?

Newer hospitals supplied 28% of Yatharth’s Q2 FY27 revenue mix, compared with 11% in Q2 FY26. The company defines the newer-hospital group as Greater Faridabad, New Delhi Model Town, Faridabad Sector-20 and Agra, while stating that existing hospitals generated EBITDA margins of about 28% or more.

Faridabad Sector-20 generated Rs 40 crore of Q2 FY27 revenue, or about 9% of group revenue, and was EBITDA profitable after reaching EBITDA breakeven in nine months. Its latest monthly revenue was about Rs 15 crore, latest average revenue per occupied bed, or ARPOB, was about Rs 40,000, and radiation oncology is expected from H2 FY27.

Model Town generated Rs 26 crore in Q2 FY27, about 6% of revenue, with latest monthly revenue of about Rs 10 crore and ARPOB of about Rs 50,000. Yatharth expects Model Town to reach EBITDA breakeven in H2 FY27, while its transplant programme approval is underway and radiation oncology remains in the pipeline.

Agra contributed Rs 20 crore in Q2 FY27, or about 5% of revenue, and was EBITDA profitable in the quarter. The facility’s latest monthly revenue was about Rs 9 crore, latest ARPOB was about Rs 33,000, and it had completed more than 200 robotic surgeries to date, according to the presentation.

What operating measures are relevant to Yatharth's expansion?

Yatharth’s Q2 FY27 occupancy reached 72% on 1,820 operational census beds, compared with 66% on 1,535 beds in Q2 FY26. Total bed capacity in the operating tracker was 2,555 in Q2 FY27, versus 2,305 a year earlier, while the company notes that occupancy is calculated on operational census beds rather than total capacity.

ARPOB increased to Rs 35,948 in Q2 FY27 from Rs 32,426 in Q2 FY26, while average length of stay declined to 3.3 days from 4.0 days. Combined inpatient department and outpatient department volumes rose to 194,000 from 130,000, comprising 36,000 inpatient visits and 158,000 outpatient visits in Q2 FY27.

Inpatient revenue increased to Rs 373.9 crore in Q2 FY27 from Rs 251 crore in Q2 FY26, while outpatient revenue rose to Rs 57.5 crore from Rs 32 crore. Yatharth says New Delhi, Faridabad Sector-20, Agra and Gurugram are yet to fully ramp up, so operational census beds are expected to increase progressively.

What must happen before Advent's investment proceeds?

Regulatory approvals must be obtained before Advent’s proposed Rs 3,150 crore primary investment proceeds. Until those approvals are received, the 24.9% Advent stake and the Tyagi family’s expected holding of about 42% remain proposed post-dilution outcomes.

The presentation does not disclose an approval timetable, a closing date or conditions beyond regulatory approvals. It does, however, identify operating milestones for H2 FY27, including Model Town’s expected EBITDA breakeven and Faridabad Sector-20’s expected radiation-oncology launch.

Yatharth also includes a 250-bed under-construction hospital in Gurugram in its stated capacity disclosure and says the facility will start with ARPOB of Rs 50,000. Whether the proposed capital closes before, during or after this ramp-up is not specified in the presentation.

Conclusion

The disclosed transaction would add Rs 3,150 crore of primary capital and a 24.9% Advent stake while preserving the Tyagi family as Yatharth’s largest shareholder at about 42% after dilution. The proposal comes after Q2 FY27 revenue rose 52% to Rs 431.4 crore and the newer-hospital revenue mix increased to 28% from 11% a year earlier.

The next event to watch is the regulatory approval process, for which Yatharth provides no timetable. On execution, the disclosed H2 FY27 milestones are Model Town’s expected EBITDA breakeven and the planned radiation-oncology launch at Faridabad Sector-20, alongside the ramp-up of the 250-bed Gurugram hospital.